

AMENDMENTS TO THE CLAIMS

Claims 1-72 (Cancelled).

73. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratadine in a free base form and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein wherein: the desloratadine does not form a pharmaceutically acceptable salt with the antioxidant; about 0.1% to about 10% of the at least one pharmaceutically acceptable antioxidant is present; at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes; minutes; and the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

74-89. (Cancelled)

90. (Currently amended) A solid composition comprising about 5 mg of desloratadine in a free base form and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein wherein: the desloratadine does not form a pharmaceutically acceptable salt with the antioxidant; about 0.1% to about 10% of the at least one pharmaceutically acceptable antioxidant is present; at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes; minutes; and the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

91-92. (Cancelled)

93. (Currently amended) A solid composition whose ingredients comprise: comprising:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0

Microcrystalline Cellulose <u>NF/Ph. Eur./JP</u>	132.7
Eddetate Disodium <u>USP</u>	10.0
Citric Acid <u>Anhydrous, USP Anhydrous</u>	10.0
Stearic Acid, <u>NF Acid</u>	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

94. (Previously presented) The solid composition of claim 93 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

95. (Currently amended) A solid composition whose ingredients comprise: comprising:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch <u>NF/Ph. Eur.</u>	18.0
Microcrystalline Cellulose <u>NF/Ph. Eur./JP</u>	66.35
Eddetate Disodium	5.0
Citric Acid	5.0
Stearic Acid <u>USP/Ph. Eur.</u>	3.0
Dye	0.15
TOTAL	100.00

and wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

96. (Previously presented) The solid composition of claim 95 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

97-98. (Cancelled)

99. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 75~~ claim 90.

100. (Cancelled)

101. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratadine in a free base form and a desloratadine-protective amount of two pharmaceutically acceptable antioxidants, ~~wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight~~, wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid, and wherein: ~~the desloratadine does not form a pharmaceutically acceptable salt with the antioxidant; about 0.1% to about 10% of the two pharmaceutically acceptable antioxidants is present; at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes; and the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.~~

102-104. (Cancelled)

105. (Currently amended) A solid composition comprising about 2.5 mg desloratadine in a free base form and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, ~~wherein wherein: the desloratadine does not form a pharmaceutically acceptable salt with the antioxidant; about 0.1% to about 10% of the at least one pharmaceutically acceptable antioxidant is present; at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes; and the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.~~

106. (Currently amended) A solid composition ~~whose ingredients comprise:~~ comprising:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	140.7

Edetate Disodium	10.0
Citric Acid	2.0
Talc NF/Ph. Eur.	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

107. (Previously presented) The solid composition of claim 106 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

108. (Currently amended) A solid composition ~~whose ingredients comprise:~~ comprising:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	70.35
Edetate Disodium	5.0
Citric Acid	1.0
Talc NF/Ph. Eur.	3.0
Dye	0.28
TOTAL	100.00

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

109. (Previously presented) The solid composition of claim 108 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

110-116. (Cancelled)

117. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 101.

118. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 105.

119. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

120. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.

121. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 73.